Physician profile
Sapna Singh
NPI 1306934864
$2,495.62
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $218 · 2021: $399 · 2022: $327 · 2023: $212 · 2024: $406 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $721.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.76 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $255.36 | 2021-2025 | |
| Biotissue Holdings INC. | $231.32 | 2024-2025 | |
| Lilly USA, LLC | $155.51 | 2019-2025 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.14 | 2020-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $96.05 | 2024-2025 | Benlysta, Shingrix |
| Horizon Therapeutics Plc | $88.46 | 2019-2021 | |
| Astellas Pharma US INC | $77.98 | 2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $73.82 | 2020-2021 | |
| Exact Sciences Corporation | $57.13 | 2024-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $50.69 | 2020-2021 | |
| Emmaus Medical, INC. | $46.71 | 2022-2023 | Endari |
| Astrazeneca Pharmaceuticals LP | $30.02 | 2020-2024 | Breztri |
| Kowa Pharmaceuticals America, INC. | $28.49 | 2023 | Livalo, Seglentis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.44 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.14 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.20 | 2025 | Jynarque |
| Kyowa Kirin, INC. | $19.12 | 2025 | |
| Ossdsign USA Incorporated | $18.73 | 2025 | Ossdsign Catalyst |
| Xeris Pharmaceuticals, INC. | $15.99 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $13.18 | 2023 | |
| Amgen INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.